Compare TNGX & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNGX | MIR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 6.0B |
| IPO Year | N/A | N/A |
| Metric | TNGX | MIR |
|---|---|---|
| Price | $8.74 | $23.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $12.50 | ★ $28.29 |
| AVG Volume (30 Days) | 2.7M | ★ 3.2M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | $66,501,000.00 | ★ $902,300,000.00 |
| Revenue This Year | $53.01 | $8.15 |
| Revenue Next Year | N/A | $19.02 |
| P/E Ratio | ★ N/A | $237.92 |
| Revenue Growth | ★ 53.29 | 7.82 |
| 52 Week Low | $1.03 | $12.00 |
| 52 Week High | $11.20 | $30.28 |
| Indicator | TNGX | MIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 38.03 |
| Support Level | $8.89 | $24.52 |
| Resistance Level | $10.08 | $26.36 |
| Average True Range (ATR) | 0.62 | 1.03 |
| MACD | -0.17 | -0.19 |
| Stochastic Oscillator | 8.57 | 1.44 |
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.